PharmaCyte Biotech, Inc.
PMCB
$1.04
$0.032.97%
NASDAQ
| 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.52M | 3.94M | 4.10M | 5.00M | 5.31M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.96M | 4.38M | 4.50M | 5.41M | 5.71M |
| Operating Income | -3.96M | -4.38M | -4.50M | -5.41M | -5.71M |
| Income Before Tax | -1.13M | 30.66M | 20.25M | 22.68M | 26.94M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.13 | 30.66 | 20.25 | 22.68 | 26.94 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.13M | 30.66M | 20.25M | 22.68M | 26.94M |
| EBIT | -3.96M | -4.38M | -4.50M | -5.41M | -5.71M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.30 | 2.83 | 0.95 | 0.73 | 0.69 |
| Normalized Basic EPS | -0.09 | 0.50 | 0.84 | 0.52 | 0.49 |
| EPS Diluted | -0.30 | 2.83 | 0.95 | 0.73 | 0.69 |
| Normalized Diluted EPS | -0.09 | 0.50 | 0.84 | 0.52 | 0.49 |
| Average Basic Shares Outstanding | 28.25M | 29.32M | 30.81M | 32.46M | 33.59M |
| Average Diluted Shares Outstanding | 28.25M | 29.32M | 30.81M | 32.46M | 33.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |